Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria could hold key to better epilepsy treatment

NCT ID NCT07253701

Knowledge-focused Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study looks at how bacteria in the gut and mouth are linked to epilepsy and whether they affect how well seizure medicines work. Researchers will collect stool, saliva, and blood samples from 1,500 people with newly diagnosed epilepsy and healthy controls. By analyzing these samples, they hope to find patterns that could one day help doctors personalize epilepsy treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors choose the best seizure medicine based on a person's gut bacteria, improving seizure control and reducing side effects.
What could go wrong
This is an observational study, not a treatment trial. It may find no clear links between gut bacteria and epilepsy, or the results may not lead to practical changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Residents of Sweden

Ages

2 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients: Age 2-79 years, newly diagnosed with epilepsy, treatment-naive at time of enrollment * Controls: Age 2-79 years Exclusion Criteria: * Patients: already started ASM treatment (more then one dose), has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy * Controls: previous epilepsy diagnosis or ASM treatment, has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarker discovery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy metabolic disease visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarker discovery Epilepsy Metabolomics Microbiota Proteomics

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akademiska Sjukhuset

    RECRUITING

    Uppsala, Sweden

  • Drottning Silvias Barnsjukhus

    RECRUITING

    Gothenburg, Sweden

  • Karolinska Universitetssjukhus

    RECRUITING

    Stockholm, Sweden

  • Norrlands universitetssjukhus

    RECRUITING

    Umeå, Sweden

  • Skånes universitetssjukhus

    RECRUITING

    Lund, Sweden

  • Universitetssjukhuset i Linköping

    RECRUITING

    Linköping, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.